Phase 4
Completed N=40
Topical Steroid Formulation and Wet Wraps
Dermatitis, Atopic
Source: ClinicalTrials.gov NCT02680301 ↗
Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Sep 2018
Primary outcomePrimary: Efficacy of 0.1% Triamcinolone Containing Wet Wrap as an Ointment or as a Cream Formulation in Patients With Moderate to Severe Atopic Dermatitis — 0.717; 0.589 units on a scale — p=0.22
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The purpose of this study is to
1. Compare efficacy of 0.1% triamcinolone containing wet wrap as an ointment or as a cream formulation in patients with moderate to severe atopic dermatitis
2. The relative patient/subject acceptance and adherence will also be compared between the two wet wrap types
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Efficacy of 0.1% Triamcinolone Containing Wet Wrap as an Ointment or as a Cream Formulation in Patients With Moderate to Severe Atopic Dermatitis |
0.717; 0.589 | 0.22 |
| SECONDARY Patient Reported Efficacy |
9; 16; 14 | — |
Eligibility Criteria
Inclusion Criteria
- Patients between the ages of 3-17 experiencing a symmetric, bilateral flare of atopic dermatitis
- The flares must reach a certain threshold for inclusion based on the investigator's global assessment scale
Exclusion Criteria
- Systemic infection or bacterial skin infections
- Eczema herpeticum
- Evidence of suppression of the Hypothalamic-Pituitary-Adrenal axis
- Non-English or Non-Spanish speaking
Data sourced from ClinicalTrials.gov (NCT02680301). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.